Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with <i>PIK3CA</i> Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.
Authors
- Mariana Paes Dias (ORCID: https://orcid.org/0000-0002-5757-4211)
- Sònia Servitja (ORCID: https://orcid.org/0000-0001-6988-4519)
- Pablo Tolosa (ORCID: https://orcid.org/0000-0002-3747-4766)
- Joaquín Gavilá Gregori (ORCID: https://orcid.org/0000-0002-6768-3833)
- Xavier González (ORCID: https://orcid.org/0000-0002-5797-7037)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- Milana A. Bergamino (ORCID: https://orcid.org/0000-0002-1091-2711)
- J.M. Ferrero-Cafiero (ORCID: https://orcid.org/0000-0001-8796-8812)
- Tomás Pascual (ORCID: https://orcid.org/0000-0001-8431-3183)
- Javier Salvador Bofill (ORCID: https://orcid.org/0000-0003-3043-4398)
- Mafalda Oliveira (ORCID: https://orcid.org/0000-0001-9152-8799)
- Alexandra Cortegoso (ORCID: https://orcid.org/0000-0003-4098-9266)
- Fernando Henao (ORCID: https://orcid.org/0000-0003-3819-9572)
- Fernando Salvador (ORCID: https://orcid.org/0000-0002-5442-1754)
- Eva Ciruelos (ORCID: https://orcid.org/0000-0002-2796-1042)
- Cristina Saura (ORCID: https://orcid.org/0000-0001-8296-5065)
- Serafin M. Morales (ORCID: https://orcid.org/0000-0001-7445-4193)
- Vanesa Quiroga (ORCID: https://orcid.org/0000-0002-7852-474X)
- Samyukta Chillara (ORCID: https://orcid.org/0000-0002-6072-5455)
- Estela Vega (ORCID: https://orcid.org/0009-0005-5652-6460)
Institutions
- Hebron University (PS)
- Universitat Pompeu Fabra (ES)
- Universidade de Santiago de Compostela (ES)
- Hospital Universitari Arnau de Vilanova (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital Universitario Virgen Macarena (ES)
- Instituto Oncológico Dr. Rosell (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Centro Oncológico de Galicia (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Institut Català d'Oncologia (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario HM Madrid (ES)
- Hospital Arnau de Vilanova (ES)
- Hospital General de Catalunya (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Del Mar (ES)
- Solti (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Spanish Ovarian Cancer Research Group (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2298
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- F. Hoffmann-La Roche
- Fundación BBVA
- Les Laboratories Pierre Fabre
- Veracyte
- Relay Therapeutics
- Seagen
- Daiichi-Sankyo
- Eisai
- Banco Bilbao Vizcaya Argentaria
- European Society for Medical Oncology
- Genentech
- Instituto de Salud Carlos III
- Daiichi Sankyo Europe